Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Atea Pharmaceuticals, Inc. - common stock (NQ:AVIR)

4.460 +0.300 (+7.21%)
Streaming Delayed Price Updated: 3:58 PM EST, Feb 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Atea Pharmaceuticals, Inc. - common stock

< Previous 1 2 3 Next >
News headline image
Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals to Host Third Quarter 2025 Financial Results and Business Update Conference Call on November 12, 2025
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025
Company Hosting Virtual KOL Panel Event Thursday, November 13th at 10:00 AM ET 
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals to Host Virtual HCV KOL Panel Event on November 13, 2025
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals to Present New Data Supporting Combination of Bemnifosbuvir and Ruzasvir as Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals to Host Second Quarter 2025 Financial Results and Business Update Conference Call on August 7, 2025
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program
Enters into Agreement with Bradley L. Radoff and Michael Torok 
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors
From On Behalf of The Radoff-JEC Group
Via Business Wire
News headline image
Atea Pharmaceuticals Issues Statement Regarding Director Nominations
No Shareholder Action is Required at this Time 
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals Announces Presentation of Bemnifosbuvir Preclinical Data at the 38th International Conference on Antiviral Research (ICAR) 2025
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on March 6, 2025
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals to Highlight 2025 Strategic Priorities at the 43rd Annual J.P. Morgan Healthcare Conference
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV)
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.